THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q4 2019 13F Holders as of 31 Dec 2019

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
100.48%
Total 13F principal
$226,932,471
Principal change
+$67,255
Total reported market value
$230,037,109
Number of holders
26
Value change
+$409,851
Number of buys
12
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q4 2019

As of 31 Dec 2019, THERAVANCE INC - CORPORATE OBLIG was held by 26 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $226,932,471 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, Antara Capital LP, ADVENT CAPITAL MANAGEMENT /DE/, LAZARD ASSET MANAGEMENT LLC, CNH PARTNERS LLC, BANK OF AMERICA CORP /DE/, CSS LLC/IL, NEW YORK STATE COMMON RETIREMENT FUND, CITADEL ADVISORS LLC, and Castle Creek Arbitrage, LLC. This page lists 26 institutional bondholders reporting positions for the Q4 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.